FDA approves Revolution Medicines' RASONQUE (daraxonrasib) for previously treated metastatic pancreatic adenocarcinoma
Revolution Medicines disclosed that on August 26, 2026, the U.S. FDA approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval was based on data from the global, randomized Phase 3 RASolute 302 trial evaluating RASONQUE versus investigator's choice of cytotoxic chemotherapy in previously treated metastatic pancreatic adenocarcinoma. On...
Key takeaways
FDA approved RASONQUE (daraxonrasib) on August 26, 2026 for previously treated metastatic pancreatic adenocarcinoma in adult patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Approval was supported by the global, randomized Phase 3 RASolute 302 trial comparing RASONQUE versus investigator's choice of cytotoxic chemotherapy in previously treated metastatic pancreatic adenocarcinoma.
RASONQUE is now commercially available in the United States as a once-daily oral tablet for eligible patients.
Wholesale acquisition cost is $39,800 for a 30-day supply based on the recommended daily dose.
The disclosure was filed as a Form 8-K Item 8.01 Other Events and did not include financial results, guidance updates, or call/webcast details.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow RVMD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.